The Food and Drug Administration (FDA) has approved two immunotherapeutic drugs targeting PD-1 -pembrolizumab and nivolumab for the treatment of relapsed and metastatic HNSCC (Head and Neck Squamous Cell Carcinoma. This evidence concerns the gene PDCD1 and head and neck squamous cell carcinoma.